[A Novel Oral Anti-osteoporosis Drug with Osteogenesis-promoting Effects via Osteoblast Differentiation].

In conclusion, KY-273 is a promising candidate for use as an oral anti-osteoporosis drug with osteogenesis promoting effects.
PMID: 30606923 [PubMed - in process]

Source: Yakugaku Zasshi : Journal of the Pharmaceutical Society of Japan - January 6, 2019 Category: Drugs & Pharmacology Authors: Kitao T, Ito Y, Fukui M, Yamamoto M, Shoji Y, Takeda S, Shirahase H Tags: Yakugaku Zasshi Source Type: research